EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Advances in the Biosynthetic Production of Daunomycin: Genetic, Metabolic, and Process Engineering Strategies

Alexandra Cristina Blaga, Irina Cârlescu, Ioan Mămăligă, Elena Niculina Drăgoi

Fermentation · 26.06.2026 · 12 (7) · 304

DOI: 10.3390/fermentation12070304 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Fermentation, online erschienen am 26.06.2026. Verfasst von Alexandra Cristina Blaga und 3 weiteren Autor:innen. Die Arbeit nennt 131 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Daunomycin (daunorubicin) is one of the most clinically significant anthracyclines used in chemotherapy, and its efficient production remains a major objective for biotechnological researchers. Industrial manufacturing relies on the fermentation of Streptomyces peucetius and Streptomyces coeruleorubidus, which produce daunomycin as a secondary metabolite under controlled conditions. This review will focus on the methods to enhance the total efficiency of biotechnological production, from upstream biosynthesis to downstream processing. Given the complexity of the daunomycin biosynthetic pathway in Streptomyces spp., substantial progress has been made in strain improvement to increase yield, metabolic robustness, and process stability. Advances in classical mutagenesis, pathway engineering, regulatory network modulation, and precursor supply optimization, along with rational medium design and advanced process control, have led to substantial increases in product titers and productivity. At the same time, innovations in downstream processes, such as extraction, purification and process integration, have increased recovery efficiency, product quality, and economic feasibility. With improvements in the production process, novel drug delivery modalities have been developed (e.g., drug carriers based on erythrocytes, drug nanocarriers based on hyaluronic acid) with increased efficiency and lower systemic toxicity. These developments indicate an evolution from pathway-level engineering to industrial-scale manufacturing and clinical application, underlining the evolution of daunomycin research and biotechnological production.

Zitieren

APA

Blaga, A. C., Cârlescu, I., Mămăligă, I., & Drăgoi, E. N. (2026). Advances in the Biosynthetic Production of Daunomycin: Genetic, Metabolic, and Process Engineering Strategies. Fermentation, 12(7), 304. https://doi.org/10.3390/fermentation12070304

Vancouver

Blaga AC, Cârlescu I, Mămăligă I, Drăgoi EN. Advances in the Biosynthetic Production of Daunomycin: Genetic, Metabolic, and Process Engineering Strategies. Fermentation. 2026;12(7):304. doi:10.3390/fermentation12070304

BibTeX
@article{Blaga2026,
  author = {Blaga, Alexandra Cristina and Cârlescu, Irina and Mămăligă, Ioan and Drăgoi, Elena Niculina},
  title = {Advances in the Biosynthetic Production of Daunomycin: Genetic, Metabolic, and Process Engineering Strategies},
  journal = {Fermentation},
  year = {2026},
  volume = {12},
  number = {7},
  pages = {304},
  doi = {10.3390/fermentation12070304}
}
Kostenlos starten →